US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

AI Healthcare

506.34

+5.461.09%

Number of Gainers:3

Number of Losers:1

Number of Flat:- -

PE:- -

High:521.94

Open:498.04

Low:489.68

Close:500.88

Loading ...

Beam Therapeutics Inc.'s (NASDAQ:BEAM) recent 11% pullback adds to one-year year losses, institutional owners may take drastic measures

Simply Wall St.

CRISPR Therapeutics AG (CRSP) Stock Moves -1.81%: What You Should Know

Recursion Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley

Beam Therapeutics (BEAM) Moves 12.6% Higher: Will This Strength Last?

Thermo Fisher (TMO) Surges 8.2%: Is This an Indication of Further Gains?

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries

Why Tempus AI Inc. (TEM) Went Down On Tuesday?

Recursion Pharmaceuticals Doses First Patient in Phase 1 Trial of Potential B-Cell Lymphoma Treatment

MT Newswires Live

Press Release: Cass Information Systems Sells Telecom Expense Management Business to Asignet

Recursion Announces First Patient Dosed in Phase 1 Clinical Study of Rec-3565, a Selective Malt1 Inhibitor for Relapsed or Refractory B-Cell Lymphomas

THOMSON REUTERS

Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas

Beam Therapeutics Presents Biomarker Data For BEAM-302 Gene Therapy For Inherited Disease

4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street

Beam Therapeutics (BEAM) Gets a Buy from Scotiabank

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/BK4611/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4611","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4611\",,,,,undefined,":{"symbol":"BK4611","market":"US","secType":"PLATE","nameCN":"AI Healthcare","latestPrice":506.3424,"timestamp":1745265599999,"preClose":500.88416,"halted":0,"volume":27338411,"delay":0,"changeRate":0.010897,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":5.458252,"latestTime":"04-21 16:00:00 EDT","open":498.04114,"high":521.93506,"low":489.6835,"amount":556144523.493927,"amplitude":0.064389,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1745280000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":3.744561,"peRate":-7.355623,"turnoverRate":0.04291,"increases":3,"decrements":1,"flats":0,"marketCap":14285330688,"floatMarketCap":10629884160},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4611\",,,,,undefined,":{"symbol":"BK4611","high":521.93506,"amplitude":0.064389,"preClose":500.88416,"low":489.6835,"pbRate":"3.744561","latestPrice":506.3424,"volume":27338411,"delay":0,"open":498.04114,"prevYearClose":530.4984,"prevWeekClose":500.8842,"prevMonthClose":527.803,"prevQuarterClose":527.803,"fiveDayClose":514.1271,"twentyDayClose":609.3474,"sixtyDayClose":658.7855,"secType":"PLATE","market":"US","turnoverRate":0.04291,"peRate":-7.355623,"marketCap":14285330688,"floatMarketCap":10629884160,"timestamp":1745265599999,"nameCN":"AI Healthcare"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4611\",,,,undefined,":{"bkCode":"BK4611","up":3,"down":1,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4611\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2526664088","title":"Beam Therapeutics Inc.'s (NASDAQ:BEAM) recent 11% pullback adds to one-year year losses, institutional owners may take drastic measures","url":"https://stock-news.laohu8.com/highlight/detail?id=2526664088","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526664088?lang=en_us&edition=fundamental","pubTime":"2025-04-11 19:37","pubTimestamp":1744371466,"startTime":"0","endTime":"0","summary":"Given the large stake in the stock by institutions, Beam Therapeutics' stock price might be vulnerable to their trading decisions. A total of 7 investors have a majority stake in the company with 51% ownership. Ownership research along with  analyst forecasts data  help provide a good understanding of opportunities in a stock. Every investor in Beam Therapeutics Inc.  should be aware of the most powerful shareholder groups. And the group that holds the biggest piece of the pie are institutions with 80% ownership. Put another way, the group faces the maximum upside potential .Institutional investors own over 50% of the company, so together than can probably strongly influence board decisions. Our data indicates that hedge funds own 8.5% of Beam Therapeutics. That worth noting, since hedge funds are often quite active investors, who may try to influence management. Many want to see value creation  in the short term or medium term. Our data shows that FMR LLC is the largest s","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beam-therapeutics-inc-nasdaq-beam-113746956.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MNQmain","BEAM","LU2095319765.USD","SQQQ","QLD","USAW.SI","USJW.SI","TSYW.SI","NQmain","PSQ","IE00B64PRP62.GBP","TQQQ","LU2210149790.SGD","BK4535","BK4505","LU2210150020.SGD","BK4112","BK4588","BK4556","QID","NVIW.SI","BK4611",".IXIC","BK4585","BK4139","IE00BGHQF748.EUR","NDAQ","IE00BKPKM429.USD","IE00B3QW5Z07.USD"],"gpt_icon":1},{"id":"2526525917","title":"CRISPR Therapeutics AG (CRSP) Stock Moves -1.81%: What You Should Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2526525917","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526525917?lang=en_us&edition=fundamental","pubTime":"2025-04-11 05:50","pubTimestamp":1744321811,"startTime":"0","endTime":"0","summary":"In the latest trading session, CRISPR Therapeutics AG  closed at $34.26, marking a -1.81% move from the previous day. This change was narrower than the S&P 500's daily loss of 3.46%. Elsewhere, the Dow lost 2.5%, while the tech-heavy Nasdaq lost 4.31%.The the stock of company has fallen by 19.78% in the past month, lagging the Medical sector's loss of 10.85% and the S&P 500's loss of 5.27%.Market participants will be closely following the financial results of CRISPR Therapeutics AG in its upcoming release. The company is expected to report EPS of -$1.26, up 11.89% from the prior-year quarter. Our most recent consensus estimate is calling for quarterly revenue of $5.24 million, up 947.2% from the year-ago period.Investors should also note any recent changes to analyst estimates for CRISPR Therapeutics AG. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the company's b","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/crispr-therapeutics-ag-crsp-stock-215011874.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4585","CRSP","BK4556","BK4611","LU1861559042.SGD","LU1861558580.USD","BK4210","AG","BK4588","BK4139"],"gpt_icon":0},{"id":"2526451593","title":"Recursion Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2526451593","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526451593?lang=en_us&edition=fundamental","pubTime":"2025-04-11 00:23","pubTimestamp":1744302180,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/RXRX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 10, 2025 12:23 ET (16:23 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"a9b4e43bbb37604adaeb10a55d437a8b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2347655156.SGD","BK4539","LU1989772840.SGD","LU0971096721.USD","BK4581","LU0314104364.USD","LU2271345857.HKD","LU0267386448.USD","LU1668664300.SGD","LU1732799900.SGD","BK4534","LU2111349929.HKD","LU1162221912.USD","LU0158827781.USD","LU1074936037.SGD","BK4585","LU2028103732.USD","LU0795875169.SGD","IE00BZ1G4Q59.USD","RXRX","LU2133065610.SGD","LU0006306889.USD","LU2023251221.USD","BK4504","LU0158827948.USD","LU2089283258.USD","BK4609","BK4127","LU1548497426.USD","LU1720051017.SGD","LU1720051108.HKD","BK4516","LU0106831901.USD","LU0320765646.SGD","BK4588","BK4611","LU0795875086.SGD","LU1363072403.SGD","BK4139","LU2357305700.SGD","LU0912757837.SGD","LU1732800096.USD","LU0098860793.USD","LU2089284900.SGD","LU1989772923.USD","BK4548","LU0106261372.USD","IE00BKVL7J92.USD","LU0225283273.USD"],"gpt_icon":0},{"id":"2526518905","title":"Beam Therapeutics (BEAM) Moves 12.6% Higher: Will This Strength Last?","url":"https://stock-news.laohu8.com/highlight/detail?id=2526518905","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526518905?lang=en_us&edition=fundamental","pubTime":"2025-04-10 21:49","pubTimestamp":1744292940,"startTime":"0","endTime":"0","summary":"Beam Therapeutics Inc.  shares ended the last trading session 12.6% higher at $16.37. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 45% loss over the past four weeks.The stock surged in response to the broader market rally after President Trump announced a 90-day pause on the sweeping tariffs against non-retaliating countries.This company is expected to post quarterly loss of $1.11 per share in its upcoming report, which represents a year-over-year change of +8.3%. Revenues are expected to be $15.34 million, up 107% from the year-ago quarter.For Beam Therapeutics, the consensus EPS estimate for the quarter has been revised 4.6% higher over the last 30 days to the current level. And a positive trend in earnings estimate revision usually translates into price appreciation. So, make sure to keep an eye on BEAM going forward to see if this recent jump can turn into more strength down the road.Th","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beam-therapeutics-beam-moves-12-134900338.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4611","MGTX","BK4139","BEAM","BK4585","BK4535","BK4588","BK4505","BK4556"],"gpt_icon":0},{"id":"2526552248","title":"Thermo Fisher (TMO) Surges 8.2%: Is This an Indication of Further Gains?","url":"https://stock-news.laohu8.com/highlight/detail?id=2526552248","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526552248?lang=en_us&edition=fundamental","pubTime":"2025-04-10 17:15","pubTimestamp":1744276500,"startTime":"0","endTime":"0","summary":"Thermo Fisher Scientific TMO shares ended the last trading session 8.2% higher at $453.55. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 18.5% loss over the past four weeks.Thermo Fisher scored a strong price increase, on investors’ optimism surrounding its impending 2025 first-quarter financial results, which is slated to release on April 23 before the opening bell. In the last reported quarter, the company achieved robust revenue growth across all product categories. Additionally, market is also upbeat about the company’s launch of latest customer-centric innovation, the Thermo Scientific Krios 5 Cryo-Transmission Electron Microscope .This maker of scientific instrument and laboratory supplies is expected to post quarterly earnings of $5.11 per share in its upcoming report, which represents no change from the year-ago quarter. Revenues are expected to be $10.25 billion, down 0.9% from the ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/thermo-fisher-tmo-surges-8-091500360.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","LU2041044095.USD","LU0096362180.USD","IE00BJJMRZ35.SGD","BK4611","LU0061474960.USD","ARAY","BK4585","LU1854103824.USD","IE0009355771.USD","LU2089984988.USD","BK4082","LU1989771016.USD","LU0882574055.USD","LU2125909247.SGD","LU2211815571.USD","LU1548497426.USD","LU2764263039.SGD","LU1720051108.HKD","IE00BJT1NW94.SGD","LU2357305700.SGD","LU1983299246.USD","TMO","LU2764262908.HKD","LU2298321311.HKD","LU2063271972.USD","LU1291159041.SGD","IE00B2B36J28.USD","LU1023059063.AUD","LU1153585028.USD","LU2125909593.SGD","LU0011850046.USD","LU2092937221.SGD","BK4613","LU2264538146.SGD","LU1861558580.USD","LU1815333072.USD","LU0640476718.USD","LU2125909916.SGD","LU1791710400.SGD","IE00B19Z8W00.USD","LU1064131342.USD","GB00BDT5M118.USD","LU0342679015.USD","LU2125910336.SGD","LU2468319806.SGD","LU1854104046.USD","IE00BKPKM429.USD","IE00BFTCPJ56.SGD"],"gpt_icon":1},{"id":"2526937643","title":"CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know","url":"https://stock-news.laohu8.com/highlight/detail?id=2526937643","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526937643?lang=en_us&edition=fundamental","pubTime":"2025-04-09 21:00","pubTimestamp":1744203608,"startTime":"0","endTime":"0","summary":"CRISPR Therapeutics AG  has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.Over the past month, shares of this company have returned -26.2%, compared to the Zacks S&P 500 composite's -13.5% change. During this period, the Zacks Medical - Biomedical and Genetics industry, which CRISPR Therapeutics falls in, has lost 17.7%. The key question now is: What could be the stock's future direction?Although media reports or rumors about a significant change in a company's business prospects usually cause its stock to trend and lead to an immediate price change, there are always certain fundamental factors that ultimately drive the buy-and-hold decision.While earnings growth is arguably the most superior indicator of a company's financial health, nothing happens as such if a business isn't able to grow its revenues. After all, it's nearly impossible for a c","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/crispr-therapeutics-ag-crsp-attracting-130008048.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4210","BK4556","BK4611","LU1861558580.USD","AG","LU1861559042.SGD","CRSP","BK4139","BK4585"],"gpt_icon":1},{"id":"2526559363","title":"Recursion and Enamine Release New AI-Enabled Targeted Compound Libraries","url":"https://stock-news.laohu8.com/highlight/detail?id=2526559363","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526559363?lang=en_us&edition=fundamental","pubTime":"2025-04-09 20:00","pubTimestamp":1744200000,"startTime":"0","endTime":"0","summary":"Kyiv, Ukraine and Salt Lake City, UT, April  09, 2025  (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announc","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/09/3058339/0/en/Recursion-and-Enamine-Release-New-AI-Enabled-Targeted-Compound-Libraries.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4611","BK4609","RXRX","BK4539","BK4548","BK4139"],"gpt_icon":1},{"id":"2526356270","title":"Why Tempus AI Inc. (TEM) Went Down On Tuesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2526356270","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2526356270?lang=en_us&edition=fundamental","pubTime":"2025-04-09 18:15","pubTimestamp":1744193710,"startTime":"0","endTime":"0","summary":"Wall Street’s main indices suffered a bloodbath on Tuesday, recording steep losses amid the looming deadline for President Donald Trump’s new round of tariffs for China that would see the latter slapped with a cumulative 104-percent import tax.The tech-heavy Nasdaq registered the heaviest fall, down by 2.15 percent, followed by the S&P 500’s 1.57 percent decline, and the Dow Jones’ 0.84-percent drop.Ten companies mirrored the broader decline, recording hefty losses during the day. In this article, we listed the 10 worst-performing names and detailed the reasons behind their drop.To come up with the list, we considered only the stocks with $2 billion market capitalization and $5 million in trading volume.Tempus AI saw its share prices drop by 12.81 percent on Tuesday to end at $37.23 apiece amid the overall market pessimism and the lack of fresh catalysts to boost buying appetite.The company appeared to be waiting on the sidelines for more updates from the ongoing Annual Needham Virtual","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-tempus-ai-inc-tem-101510939.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU1861558580.USD","LU1861559042.SGD","BK4611","BK4613","BK4121","TEM"],"gpt_icon":1},{"id":"2525922298","title":"Recursion Pharmaceuticals Doses First Patient in Phase 1 Trial of Potential B-Cell Lymphoma Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2525922298","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525922298?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:59","pubTimestamp":1744117160,"startTime":"0","endTime":"0","summary":"Recursion Pharmaceuticals  said Tuesday the first patient has been dosed in a phase 1 clinical study of REC-3565 for the potential treatment of relapsed or refractory B-cell lymphomas.The investigational drug has demonstrated evidence of durable tumor regression in preclinical trials as a monotherapy and in combination with a BTK inhibitor, the company said.The two-part study will also evaluate REC-3565 as a monotherapy to identify a recommended dose for combination regimens, Recursion Pharmaceuticals added.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4539","BK4609","BK4548","RXRX","BK4611"],"gpt_icon":1},{"id":"2525891473","title":"Press Release: Cass Information Systems Sells Telecom Expense Management Business to Asignet","url":"https://stock-news.laohu8.com/highlight/detail?id=2525891473","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525891473?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:30","pubTimestamp":1744115400,"startTime":"0","endTime":"0","summary":"Cass Information Systems, Inc. ,  has entered into an Asset Purchase Agreement to sell its Telecom Expense Management & Managed Mobility Services  business to Asignet USA Inc. , a market-leading hyper-automation IT expense management provider.Martin Resch, the Company's President and Chief Executive Officer, said, \"The sale of our TEM business is consistent with our strategy of focusing our capital investments on our proficiencies in financial exchange and information processing. We believe this transaction will create a great deal of value for our customers given Asignet's significant investment in products and services in this space. Asignet is also a great fit for our valued employees.\". Claudio Lopez Silva, Asignet's Chief Executive Officer, said, \"We are beyond excited to welcome the Cass TEM team to the Asignet family. In addition, Cass TEM clients will enjoy best in class managed service, experience, and state of the art solution.\". Asignet's proprietary automation is powered by","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CASS","BK4121","LU1861558580.USD","LU1861559042.SGD","BK4613","BK4106","BK4611","BK4227"],"gpt_icon":1},{"id":"2525962738","title":"Recursion Announces First Patient Dosed in Phase 1 Clinical Study of Rec-3565, a Selective Malt1 Inhibitor for Relapsed or Refractory B-Cell Lymphomas","url":"https://stock-news.laohu8.com/highlight/detail?id=2525962738","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525962738?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:00","pubTimestamp":1744113604,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250408:nTUAB0P48Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4611","BK4548","BK4139","BK4539","RXRX","BK4609"],"gpt_icon":0},{"id":"2525899567","title":"Recursion Announces First Patient Dosed in Phase 1 Clinical Study of REC-3565, a Selective MALT1 Inhibitor for Relapsed or Refractory B-cell Lymphomas","url":"https://stock-news.laohu8.com/highlight/detail?id=2525899567","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525899567?lang=en_us&edition=fundamental","pubTime":"2025-04-08 20:00","pubTimestamp":1744113600,"startTime":"0","endTime":"0","summary":"REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitorsSalt Lake Ci","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/04/08/3057532/0/en/Recursion-Announces-First-Patient-Dosed-in-Phase-1-Clinical-Study-of-REC-3565-a-Selective-MALT1-Inhibitor-for-Relapsed-or-Refractory-B-cell-Lymphomas.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4611","BK4609","BK4539","RXRX","BK4548","BK4139","REC"],"gpt_icon":1},{"id":"2525402980","title":"Beam Therapeutics Presents Biomarker Data For BEAM-302 Gene Therapy For Inherited Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2525402980","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525402980?lang=en_us&edition=fundamental","pubTime":"2025-04-07 22:06","pubTimestamp":1744034788,"startTime":"0","endTime":"0","summary":"Beam Therapeutics Inc.  on Saturday presented additional data from the Phase 1/2 clinical trial of BEAM-302 in patients with alpha-1 antitrypsin deficiency  at the 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress.AATD is an inherited genetic disorder that can cause early onset emphysema and liver disease.Also Read: Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity. Initial safety and efficacy data from the Phase 1/2 trial of BEAM-302 were previouslyreported in March 2025, establishing clinical proof of concept as a potential treatment for AATD andin vivo base editing.Preliminary results from the first three single-ascending dose cohorts demonstrated that BEAM-302 was well tolerated.Single doses of BEAM-302 led to durable dose-dependent correction of the disease-causing mutation and total AAT protein levels above the therapeutic threshold in the 60 mg dose coh","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beam-therapeutics-presents-biomarker-data-140628622.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4556","BK4588","BK4505","BEAM","BK4585","BK4611","BK4535"],"gpt_icon":0},{"id":"2525017775","title":"4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street","url":"https://stock-news.laohu8.com/highlight/detail?id=2525017775","media":"Motley Fool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525017775?lang=en_us&edition=fundamental","pubTime":"2025-04-07 20:09","pubTimestamp":1744027740,"startTime":"0","endTime":"0","summary":"All four of these companies have encountered headwinds recently.Wall Street analysts think their shares have fallen far too much.Some of these drugmakers look attractive, but one seems particularly risky right now.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com/investing/2025/04/07/4-beaten-down-stocks-that-could-skyrocket-by-50-to/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"fool_stock","symbols":["LU1861558580.USD","BK4585","CRSP","LU1861559042.SGD","BK4139","BK4588","BK4556","BK4611"],"gpt_icon":0},{"id":"2525014386","title":"Beam Therapeutics (BEAM) Gets a Buy from Scotiabank","url":"https://stock-news.laohu8.com/highlight/detail?id=2525014386","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2525014386?lang=en_us&edition=fundamental","pubTime":"2025-04-07 19:16","pubTimestamp":1744024619,"startTime":"0","endTime":"0","summary":"Scotiabank analyst Greg Harrison maintained a Buy rating on Beam Therapeutics (BEAM – Research Report) today and set a price target of $40.00. The ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/beam-therapeutics-beam-gets-a-buy-from-scotiabank?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/beam-therapeutics-beam-gets-a-buy-from-scotiabank?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4585","BK4535","BK4556","BK4505","BK4588","BEAM","BK4139","BK4611"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":35,"code":"91000000","status":"200"}]}}